These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. KYNA Derivatives with Modified Skeleton; Hydroxyquinolines with Potential Neuroprotective Effect. Lőrinczi B; Szatmári I Int J Mol Sci; 2021 Nov; 22(21):. PubMed ID: 34769362 [TBL] [Abstract][Full Text] [Related]
4. Plant based food bioactives: A boon or bane for neurological disorders. Choudhary N; Tewari D; Nabavi SF; Kashani HRK; Lorigooini Z; Filosa R; Khan FB; Masoudian N; Nabavi SM Crit Rev Food Sci Nutr; 2024; 64(11):3279-3325. PubMed ID: 36369694 [TBL] [Abstract][Full Text] [Related]
5. Food-derived Peptides as Promising Neuroprotective Agents: Mechanism and Therapeutic Potential. Patel K; Mani A Curr Top Med Chem; 2024; 24(14):1212-1229. PubMed ID: 38551052 [TBL] [Abstract][Full Text] [Related]
6. Can the administration of platelet lysates to the brain help treat neurological disorders? Nebie O; Buée L; Blum D; Burnouf T Cell Mol Life Sci; 2022 Jun; 79(7):379. PubMed ID: 35750991 [TBL] [Abstract][Full Text] [Related]
7. The long road to neuroprotection for Parkinson's disease. Trenkwalder C; Mollenhauer B Lancet Neurol; 2024 Jan; 23(1):2-3. PubMed ID: 38101888 [No Abstract] [Full Text] [Related]
8. Peptides derived from growth factors: Exploring their diverse impact from antimicrobial properties to neuroprotection. Hai-Na Z; Jun-Jie J; Guang-Meng X Biomed Pharmacother; 2024 Jul; 176():116830. PubMed ID: 38824833 [TBL] [Abstract][Full Text] [Related]
9. Natural Molecules and Neuroprotection: Kynurenic Acid, Pantethine and α-Lipoic Acid. Tóth F; Cseh EK; Vécsei L Int J Mol Sci; 2021 Jan; 22(1):. PubMed ID: 33401674 [TBL] [Abstract][Full Text] [Related]
10. Parkinson's Disease and Its Management: Part 3: Nondopaminergic and Nonpharmacological Treatment Options. DeMaagd G; Philip A P T; 2015 Oct; 40(10):668-79. PubMed ID: 26535023 [TBL] [Abstract][Full Text] [Related]
11. A review on the role of quinones in renal disorders. Madeo J; Zubair A; Marianne F Springerplus; 2013 Dec; 2(1):139. PubMed ID: 23577302 [TBL] [Abstract][Full Text] [Related]
13. Pharmacological therapy in Parkinson's disease: focus on neuroprotection. Kincses ZT; Vecsei L CNS Neurosci Ther; 2011 Oct; 17(5):345-67. PubMed ID: 20438581 [TBL] [Abstract][Full Text] [Related]
14. [Neuroprotection in Parkinson's disease and other neurodegenerative disorders: preclinical and clinical findings]. Rákóczi K; Klivényi P; Vécsei L Ideggyogy Sz; 2009 Jan; 62(1-2):25-34. PubMed ID: 19248724 [TBL] [Abstract][Full Text] [Related]
15. Clinical trials of neuroprotection for Parkinson's disease. LeWitt PA Neurology; 2004 Oct; 63(7 Suppl 2):S23-31. PubMed ID: 15477583 [No Abstract] [Full Text] [Related]
16. Pharmacological aspects of the neuroprotective effects of irreversible MAO-B inhibitors, selegiline and rasagiline, in Parkinson's disease. Szökő É; Tábi T; Riederer P; Vécsei L; Magyar K J Neural Transm (Vienna); 2018 Nov; 125(11):1735-1749. PubMed ID: 29417334 [TBL] [Abstract][Full Text] [Related]
17. Preclinical evidence for neuroprotection with monoamine oxidase-B inhibitors in Parkinson's disease. Jenner P Neurology; 2004 Oct; 63(7 Suppl 2):S13-22. PubMed ID: 15477581 [No Abstract] [Full Text] [Related]
18. Neuroprotective Function of Rasagiline and Selegiline, Inhibitors of Type B Monoamine Oxidase, and Role of Monoamine Oxidases in Synucleinopathies. Naoi M; Maruyama W; Shamoto-Nagai M Int J Mol Sci; 2022 Sep; 23(19):. PubMed ID: 36232361 [TBL] [Abstract][Full Text] [Related]
19. Comprehensive review of rasagiline, a second-generation monoamine oxidase inhibitor, for the treatment of Parkinson's disease. Chen JJ; Swope DM; Dashtipour K Clin Ther; 2007 Sep; 29(9):1825-49. PubMed ID: 18035186 [TBL] [Abstract][Full Text] [Related]